DHR

Danaher Corporation

$236.11

0.42%
SectorHealthcareIndustryDiagnostics & ResearchCountryUnited States

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions.

Source: Yahoo Finance
AI summary

Price & performance

1M+4.1%
3M+28.5%
YTD+0.3%
1Y+6.1%
52-week range—
Beta0.78
Full chart and returns against a benchmark

Q-Score

55/ 100

Quality against peers; 50 is the peer median.

Growth50
Risk72
Performance43
Valuation53
Profitability61
Leverage59
Sentiment53
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$24.6B+2.9%
Net income$3.6B-7.3%
Net margin14.7%-1.6 pts
Historical fundamentals

Revenue exposure

North America42%
High-Growth Markets29%
Western Europe24%
Regions, segments, customers and suppliers

Valuation

DHRIndustryP/E38.3541.31P/S6.495.66EV/EBITDA31.1031.63P/B3.104.91PEG1.623.59
Dividend yield0.61%
Every valuation metric

Earnings

Jan 27next report, before the open
EPS estimate$1.92
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate